Molecular characteristics of clinical IMP-producing Klebsiella pneumoniae isolates: novel IMP-90 and integron In2147.


Journal

Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152

Informations de publication

Date de publication:
15 May 2023
Historique:
received: 31 01 2023
accepted: 27 04 2023
medline: 17 5 2023
pubmed: 16 5 2023
entrez: 15 5 2023
Statut: epublish

Résumé

Since the first report of carbapenem-resistant Klebsiella pneumoniae isolates in China in 2007, the prevalence of CRKP and CRE has increased significantly. However, the molecular characteristics of IMP-producing Klebsiella pneumoniae (IMPKp) are rarely reported. A total of 29 IMPKp isolates were collected from a Chinese tertiary hospital from 2011 to 2017. Clinical IMPKp were identified by VITEK Four novel ST type, including ST5422, ST5423, ST5426 and ST5427 were identified. The IMP-4 and IMP-1 were the dominant IMP type. The majority of bla IMPKp showed low prevalence in China. Novel molecular characteristics of IMPKp have been identified. Continuous monitoring of IMPKp shall also be carried out in the future.

Sections du résumé

BACKGROUND BACKGROUND
Since the first report of carbapenem-resistant Klebsiella pneumoniae isolates in China in 2007, the prevalence of CRKP and CRE has increased significantly. However, the molecular characteristics of IMP-producing Klebsiella pneumoniae (IMPKp) are rarely reported.
METHODS METHODS
A total of 29 IMPKp isolates were collected from a Chinese tertiary hospital from 2011 to 2017. Clinical IMPKp were identified by VITEK
RESULTS RESULTS
Four novel ST type, including ST5422, ST5423, ST5426 and ST5427 were identified. The IMP-4 and IMP-1 were the dominant IMP type. The majority of bla
CONCLUSIONS CONCLUSIONS
IMPKp showed low prevalence in China. Novel molecular characteristics of IMPKp have been identified. Continuous monitoring of IMPKp shall also be carried out in the future.

Identifiants

pubmed: 37189199
doi: 10.1186/s12941-023-00588-w
pii: 10.1186/s12941-023-00588-w
pmc: PMC10186765
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Informations de copyright

© 2023. The Author(s).

Références

Curr Microbiol. 2014 Feb;68(2):227-32
pubmed: 24121549
Microb Drug Resist. 2011 Mar;17(1):109-19
pubmed: 21117966
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S196-S205
pubmed: 30423057
Front Cell Infect Microbiol. 2017 Mar 30;7:102
pubmed: 28424761
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
EBioMedicine. 2017 May;19:98-106
pubmed: 28479289
mSphere. 2019 Oct 30;4(5):
pubmed: 31666316
Antimicrob Agents Chemother. 2001 Aug;45(8):2368-71
pubmed: 11451699
Antimicrob Agents Chemother. 2012 Nov;56(11):6029-32
pubmed: 22926566
Front Microbiol. 2019 Jan 14;9:3318
pubmed: 30692976
PLoS One. 2015 May 01;10(5):e0123063
pubmed: 25933288
Ann Clin Microbiol Antimicrob. 2017 Jun 19;16(1):42
pubmed: 28629366
Int J Med Microbiol. 2011 Dec;301(8):654-8
pubmed: 21992746
Antimicrob Agents Chemother. 1995 Jan;39(1):155-62
pubmed: 7695299
FEMS Microbiol Lett. 1998 Dec 15;169(2):391-5
pubmed: 9868786
Front Microbiol. 2021 Feb 17;12:626160
pubmed: 33679645
J Antimicrob Chemother. 2012 May;67(5):1121-7
pubmed: 22334605
Clin Microbiol Infect. 2013 Apr;19(4):349-55
pubmed: 22390772
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167555
Front Microbiol. 2022 Jun 16;13:929826
pubmed: 35783384
Antimicrob Agents Chemother. 2015 Feb;59(2):1356-9
pubmed: 25487806
Antimicrob Agents Chemother. 2012 Aug;56(8):4554-5
pubmed: 22664972
J Med Microbiol. 2021 Jun;70(6):
pubmed: 34170219
J Clin Microbiol. 2021 Nov 18;59(12):e0021321
pubmed: 34550809
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6853-6858
pubmed: 27600046
J Med Microbiol. 2020 May;69(5):739-747
pubmed: 32368998
Sci Rep. 2020 Mar 5;10(1):4139
pubmed: 32139745
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0200020
pubmed: 33972241
Lancet Infect Dis. 2017 Mar;17(3):256-257
pubmed: 28244381

Auteurs

Liuyang Yang (L)

Laboratory Medicine Department, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.

Guangcun Zhang (G)

Laboratory Medicine Department, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.

Qiang Zhao (Q)

Laboratory Medicine Department, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.

Ling Guo (L)

Laboratory Medicine Department, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.

Jiyong Yang (J)

Laboratory Medicine Department, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. yangjy301@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH